BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu D, Zhang Y, Wei Y, Liu G, Liu Y, Gao Q, Zou L, Zeng W, Zhang N. Activation of AKT pathway by Nrf2/PDGFA feedback loop contributes to HCC progression. Oncotarget. 2016;7:65389-65402. [PMID: 27588483 DOI: 10.18632/oncotarget.11700] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Jeong SM, Kim YJ. Astaxanthin Treatment Induces Maturation and Functional Change of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice. Antioxidants (Basel) 2020;9:E350. [PMID: 32340271 DOI: 10.3390/antiox9040350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Chen CY, Wu SM, Lin YH, Chi HC, Lin SL, Yeh CT, Chuang WY, Lin KH. Induction of nuclear protein-1 by thyroid hormone enhances platelet-derived growth factor A mediated angiogenesis in liver cancer. Theranostics 2019;9:2361-79. [PMID: 31149049 DOI: 10.7150/thno.29628] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
3 Panieri E, Saso L. Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells. Antioxid Redox Signal 2021;34:1428-83. [PMID: 33403898 DOI: 10.1089/ars.2020.8146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lin Y, Sui LC, Wu RH, Ma RJ, Fu HY, Xu JJ, Qiu XH, Chen L. Nrf2 inhibition affects cell cycle progression during early mouse embryo development. J Reprod Dev 2018;64:49-55. [PMID: 29249781 DOI: 10.1262/jrd.2017-042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
5 Sun X, Wang Y, Ji K, Liu Y, Kong Y, Nie S, Li N, Hao J, Xie Y, Xu C, Du L, Liu Q. NRF2 preserves genomic integrity by facilitating ATR activation and G2 cell cycle arrest. Nucleic Acids Res 2020;48:9109-23. [PMID: 32729622 DOI: 10.1093/nar/gkaa631] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
6 Sun J, Li P, Yang J. Repressing of NHERF1 inhibits liver cancer progression by promoting the production of ROS. Biochem Biophys Res Commun 2019;509:8-15. [PMID: 30581004 DOI: 10.1016/j.bbrc.2018.11.121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Lou D, Wei X, Xiao P, Huo Q, Hong X, Sun J, Shuai Y, Tao G. Demethylation of the NRF2 Promoter Protects Against Carcinogenesis Induced by Nano-SiO2. Front Genet 2020;11:818. [PMID: 32849814 DOI: 10.3389/fgene.2020.00818] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Ma-On C, Sanpavat A, Whongsiri P, Suwannasin S, Hirankarn N, Tangkijvanich P, Boonla C. Oxidative stress indicated by elevated expression of Nrf2 and 8-OHdG promotes hepatocellular carcinoma progression. Med Oncol. 2017;34:57. [PMID: 28281193 DOI: 10.1007/s12032-017-0914-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
9 Panieri E, Saso L. Potential Applications of NRF2 Inhibitors in Cancer Therapy. Oxid Med Cell Longev 2019;2019:8592348. [PMID: 31097977 DOI: 10.1155/2019/8592348] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 20.3] [Reference Citation Analysis]
10 He F, Antonucci L, Yamachika S, Zhang Z, Taniguchi K, Umemura A, Hatzivassiliou G, Roose-Girma M, Reina-Campos M, Duran A, Diaz-Meco MT, Moscat J, Sun B, Karin M. NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly. J Hepatol 2020;72:1182-95. [PMID: 32105670 DOI: 10.1016/j.jhep.2020.01.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
11 Yao R, Zou H, Liao W. Prospect of Circular RNA in Hepatocellular Carcinoma: A Novel Potential Biomarker and Therapeutic Target. Front Oncol. 2018;8:332. [PMID: 30191143 DOI: 10.3389/fonc.2018.00332] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
12 Haga S, Ozawa T, Morita N, Asano M, Jin S, Ozaki M. Photo-Activatable Akt Probe: A New Tool to Study the Akt-Dependent Physiopathology of Cancer Cells. Oncol Res 2018;26:467-72. [PMID: 28933316 DOI: 10.3727/096504017X15040166233313] [Reference Citation Analysis]
13 Shao Z, Pan Q, Zhang Y. Hepatocellular carcinoma cell-derived extracellular vesicles encapsulated microRNA-584-5p facilitates angiogenesis through PCK1-mediated nuclear factor E2-related factor 2 signaling pathway. Int J Biochem Cell Biol 2020;125:105789. [PMID: 32522621 DOI: 10.1016/j.biocel.2020.105789] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ding H, Wang H, Zhu L, Wei W. Ursolic Acid Ameliorates Early Brain Injury After Experimental Traumatic Brain Injury in Mice by Activating the Nrf2 Pathway. Neurochem Res 2017;42:337-46. [PMID: 27734181 DOI: 10.1007/s11064-016-2077-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
15 Panieri E, Buha A, Telkoparan-Akillilar P, Cevik D, Kouretas D, Veskoukis A, Skaperda Z, Tsatsakis A, Wallace D, Suzen S, Saso L. Potential Applications of NRF2 Modulators in Cancer Therapy. Antioxidants (Basel) 2020;9:E193. [PMID: 32106613 DOI: 10.3390/antiox9030193] [Cited by in F6Publishing: 41] [Reference Citation Analysis]
16 Zimta AA, Cenariu D, Irimie A, Magdo L, Nabavi SM, Atanasov AG, Berindan-Neagoe I. The Role of Nrf2 Activity in Cancer Development and Progression. Cancers (Basel). 2019;11. [PMID: 31717324 DOI: 10.3390/cancers11111755] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 17.0] [Reference Citation Analysis]
17 Jiang XY, Zhu XS, Xu HY, Zhao ZX, Li SY, Li SZ, Cai JH, Cao JM. Diallyl trisulfide suppresses tumor growth through the attenuation of Nrf2/Akt and activation of p38/JNK and potentiates cisplatin efficacy in gastric cancer treatment. Acta Pharmacol Sin 2017;38:1048-58. [PMID: 28344324 DOI: 10.1038/aps.2016.176] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
18 Haque E, Karim MR, Salam Teeli A, Śmiech M, Leszczynski P, Winiarczyk D, Parvanov ED, Atanasov AG, Taniguchi H. Molecular Mechanisms Underlying Hepatocellular Carcinoma Induction by Aberrant NRF2 Activation-Mediated Transcription Networks: Interaction of NRF2-KEAP1 Controls the Fate of Hepatocarcinogenesis. Int J Mol Sci 2020;21:E5378. [PMID: 32751080 DOI: 10.3390/ijms21155378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
19 Gao J, Dai C, Yu X, Yin XB, Zhou F. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway. J Cell Biochem 2021;122:86-99. [PMID: 32786108 DOI: 10.1002/jcb.29833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Meng J, Wang L, Hou J, Yang X, Lin K, Nan H, Li M, Wu X, Chen X. CCL23 suppresses liver cancer progression through the CCR1/AKT/ESR1 feedback loop. Cancer Sci 2021;112:3099-110. [PMID: 34050704 DOI: 10.1111/cas.14995] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Paiboonrungruang C, Simpson E, Xiong Z, Huang C, Li J, Li Y, Chen X. Development of targeted therapy of NRF2high esophageal squamous cell carcinoma. Cell Signal 2021;86:110105. [PMID: 34358647 DOI: 10.1016/j.cellsig.2021.110105] [Reference Citation Analysis]
22 Wang C, Ruan P, Zhao Y, Li X, Wang J, Wu X, Liu T, Wang S, Hou J, Li W, Li Q, Li J, Dai F, Fang D, Wang C, Xie S. Spermidine/spermine N1-acetyltransferase regulates cell growth and metastasis via AKT/β-catenin signaling pathways in hepatocellular and colorectal carcinoma cells. Oncotarget 2017;8:1092-109. [PMID: 27901475 DOI: 10.18632/oncotarget.13582] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
23 Maleki Dana P, Sadoughi F, Asemi Z, Yousefi B. The role of polyphenols in overcoming cancer drug resistance: a comprehensive review. Cell Mol Biol Lett 2022;27:1. [PMID: 34979906 DOI: 10.1186/s11658-021-00301-9] [Reference Citation Analysis]
24 Haider N, Larose L. Activation of the PDGFRα-Nrf2 pathway mediates impaired adipocyte differentiation in bone marrow mesenchymal stem cells lacking Nck1. Cell Commun Signal 2020;18:26. [PMID: 32059739 DOI: 10.1186/s12964-019-0506-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
25 Dai W, Jin X, Jiang B, Chen W, Ji Z, Xu X, Tang M, Dai K, Han L. Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway. Anticancer Agents Med Chem 2020;20:1933-42. [PMID: 32538734 DOI: 10.2174/1871520620666200615132435] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Lai Q, Melandro F, Larghi Laureiro Z, Giovanardi F, Ginanni Corradini S, Ferri F, Hassan R, Rossi M, Mennini G. Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: A systematic review and meta-analysis. World J Gastroenterol 2018; 24(15): 1658-1665 [PMID: 29686473 DOI: 10.3748/wjg.v24.i15.1658] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
27 Yang Y, Tian Z, Guo R, Ren F. Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways. Oxid Med Cell Longev 2020;2020:9867595. [PMID: 32765809 DOI: 10.1155/2020/9867595] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
28 He F, Antonucci L, Karin M. NRF2 as a regulator of cell metabolism and inflammation in cancer. Carcinogenesis 2020;41:405-16. [PMID: 32347301 DOI: 10.1093/carcin/bgaa039] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
29 Hu J, Li P, Song Y, Ge YX, Meng XM, Huang C, Li J, Xu T. Progress and prospects of circular RNAs in Hepatocellular carcinoma: Novel insights into their function. J Cell Physiol. 2018;233:4408-4422. [PMID: 28833094 DOI: 10.1002/jcp.26154] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
30 Chen Y, Li Y, Huang L, Du Y, Gan F, Li Y, Yao Y. Antioxidative Stress: Inhibiting Reactive Oxygen Species Production as a Cause of Radioresistance and Chemoresistance. Oxid Med Cell Longev 2021;2021:6620306. [PMID: 33628367 DOI: 10.1155/2021/6620306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Sun W, Zhang W, Yu J, Lu Z, Yu J. Inhibition of Nrf2 might enhance the anti-tumor effect of temozolomide in glioma cells via inhibition of Ras/Raf/MEK signaling pathway. Int J Neurosci 2021;131:975-83. [PMID: 32378973 DOI: 10.1080/00207454.2020.1766458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Lee YJ, Kim WI, Bae JH, Cho MK, Lee SH, Nam HS, Choi IH, Cho SW. Overexpression of Nrf2 promotes colon cancer progression via ERK and AKT signaling pathways. Ann Surg Treat Res 2020;98:159-67. [PMID: 32274363 DOI: 10.4174/astr.2020.98.4.159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]